Mizuho Maintains Buy on ResMed, Maintains $215 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Anthony Petrone reaffirmed a Buy rating on ResMed (NYSE:RMD) and maintained a $215 price target, indicating a positive outlook on the company's stock.
March 27, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Anthony Petrone reaffirmed a Buy rating on ResMed with a $215 price target, suggesting confidence in the company's future performance.
The reaffirmation of a Buy rating and a maintained price target of $215 by a reputable analyst like Anthony Petrone from Mizuho signals a strong vote of confidence in ResMed's stock. This endorsement is likely to positively influence investor sentiment and could lead to an uptick in the stock's price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100